Literature DB >> 11419988

Dura mater involvement in ochronosis (alkaptonuria).

W Liu1, R A Prayson.   

Abstract

Clinical manifestations of alkaptonuria have been well described and are most commonly characterized by ochronosis or pigmentation of connective tissue. Sites most commonly involved in ochronosis include joints, heart, skin, and kidney. We describe a 66-year-old woman with a history of alkaptonuria who had widespread ochronosis. The dura mater showed extensive pigment deposition, which was evident both grossly and microscopically at autopsy. To our knowledge, description of dura mater involvement by ochronosis has not been previously reported in the literature.

Entities:  

Mesh:

Year:  2001        PMID: 11419988     DOI: 10.5858/2001-125-0961-DMIIOA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  5 in total

1.  Fatal methemoglobinemia complicating alkaptonuria (ochronosis): a rare presentation.

Authors:  Amanda R Freeman; Stephen M Wills
Journal:  Forensic Sci Med Pathol       Date:  2018-03-23       Impact factor: 2.007

Review 2.  Acute fatal metabolic complications in alkaptonuria.

Authors:  A S Davison; A M Milan; J A Gallagher; L R Ranganath
Journal:  J Inherit Metab Dis       Date:  2015-11-23       Impact factor: 4.982

3.  Cerebro-spinal and renal ochronosis: A rare case report.

Authors:  Sunil Kumar Nanda; D R Suresh; A Vamseedhar; K Pratibha; B Arjun
Journal:  Indian J Clin Biochem       Date:  2010-05-27

4.  Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria - Is nitisinone the solution?

Authors:  A S Davison; E Luangrath; E Selvi; L R Ranganath
Journal:  Mol Genet Metab Rep       Date:  2020-04-16

5.  Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.

Authors:  Giulia Bernardini; Marcella Laschi; Michela Geminiani; Daniela Braconi; Elisa Vannuccini; Pietro Lupetti; Fabrizio Manetti; Lia Millucci; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-03-12       Impact factor: 4.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.